News | Radiation Oncology | September 13, 2019

Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019

IntelliSpace Radiation Oncology combines all the steps of the radiotherapy department’s workflow into one platform

Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019

September 13, 2019 — Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago. Visitors to the Philips booth will experience Philips IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, improve efficiency and enable operational excellence in radiotherapy departments. The company will also highlight its Pinnacle Evolution treatment planning software, as well as its broad portfolio of connected oncology solutions designed to help health systems achieve the Quadruple Aim: an improved experience for patients and staff, better health outcomes and a lower cost of care.

As the number of new cancer cases continues to rise, Philips said it is essential that care teams have access to integrated oncology solutions across all phases of oncology care to enable a more precise diagnosis, personalized therapy selection and execution, and better outcomes. Radiotherapy processes in particular can be fragmented and inefficient. By reducing uncertainties along the way, care teams can deliver seamless, targeted therapy for each individual patient.

IntelliSpace Radiation Oncology, the latest addition to Philips’ renewed suite of radiation oncology systems and software, provides a harmonized way of working, integrating applications from partners including MIM Software Inc and Sun Nuclear, and automating workflow to help reduce the amount of time it takes from receiving a patient referral to the start of their treatment. In addition, Philips’ recently launched Radiation Oncology Practice Management, a consultancy service to help radiotherapy departments capitalize on the insights and workflow improvement opportunities presented by the platform.

Philips IntelliSpace Radiation Oncology and Radiation Oncology Practice Management are considered works in progress and are not available for sale.

Read the article "Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019"

The South West Wales Cancer Centre (SWWCC) in the U.K. is among the first partner sites that will implement Philips IntelliSpace Radiation Oncology and associated practice management solutions. “This new solution should help our patients directly by improving their experience and decreasing their time to treatment,” said Russell Banner, M.D., clinical oncologist and radiotherapy lead at the SWWCC. “Furthermore, it will allow us to manage our workflows within our department, seeing where patients are within the often complex treatment pathways.”

Imaging plays a critical role in understanding tumor characteristics, increasing accuracy of therapy delivery and better assessing patient response to treatment. On-site at ASTRO this year, Philips will feature Pinnacle Evolution, the latest generation of the Philips Pinnacle treatment planning software, as well as several imaging systems, including Philips’ dedicated oncology computed tomography (CT) simulator, Big Bore RT, as well as the Ingenia Elition 3.0T magnetic resonance (MR)-RT and Ambition 1.5T MR-RT systems.

Philips’ radiation oncology portfolio complements the company’s IntelliSpace Precision Medicine oncology solutions portfolio, which integrates diagnostics and therapy selection to drive clinical, operational and financial benefits for healthcare providers. The company's oncology solutions portfolio includes:

  • Oncology Pathways – high-quality, detailed, evidence-based oncology treatment protocols powered by Dana-Farber, allowing clinical users to navigate through the branches of pathways to make clinical decisions and provide treatment plan recommendations, including clinical trials;
  • Oncology Platform – a comprehensive platform for use in multidisciplinary (and molecular) tumor board meetings, which integrates data from hospital information systems across different clinical domains including radiology, pathology and genomics, to enable a detailed view of the patient and care path to facilitate cross-disciplinary collaboration and communication;
  • Pathology – Philips’ IntelliSite Pathology Solution, the first U.S. Food and Drug Administration (FDA)-approved digital pathology solution to be marketed for primary diagnostic use to reduce pressure on pathology services by streamlining workflows and extending collaboration to help increase diagnostic confidence; and
  • Genomics – an end-to-end precision medicine platform that automates pathologists’ workflows through collaboration with oncologists and peers, enabling genomic interpretation and therapy recommendation based on a single, comprehensive patient view, which also includes OncoSignal signaling pathway activity analysis to reveal tumor-driving mechanisms.

For more information: www.usa.philips.com/healthcare

Related Content

The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
Feature | Information Technology | September 15, 2021 | By Kumar Goswami
Healthcare organizations today are storing petabytes of medical imaging data — lab slides,...
Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Feature | Radiology Imaging | September 14, 2021 | By Brendon McHugh
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.